AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12856476 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right hemisphere lesion
Number of subjects: 17
Study 12856476 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 17
Study 11783238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sijunzi Decoction (SJZD)
Number of subjects: 66
Study 9046507 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-deficient knee
Number of subjects: 8
Study 9046507 — intervention group
Group type: COMPARATOR
Intervention: Contralateral normal knee
Number of subjects: 8
Study 1647192 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC 567 (500 micrograms)
Number of subjects: 20
Study 1647192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1647192 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC 567 coadministered with bradykinin
Number of subjects: 20
Study 1647192 — intervention group
Group type: COMPARATOR
Intervention: Placebo coadministered with bradykinin
Number of subjects: 20
Study 6336918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin in conjunction with standard bowel preparation
Number of subjects: 241
Study 6336918 — intervention group
Group type: COMPARATOR
Intervention: Standard bowel preparation
Number of subjects: 241
Study 30567626 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (EVOO)
Number of subjects: 11
Study 30567626 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 11
Study 30567626 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF)
Number of subjects: 11
Study 27727063 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation arm
Number of subjects: 0
Study 27727063 — intervention group
Group type: COMPARATOR
Intervention: Standard-fractionation arm
Number of subjects: 0
Study 27727063 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive oropharyngeal cancer (OPC) patients
Number of subjects: 0
Study 27727063 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QOL/PS scores
Number of subjects: 0
Study 27015130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobi-C cervical total disc replacement
Number of subjects: 330
Study 27015130 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 330
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases with current ulcers
Number of subjects: 273
Study 24310107 — intervention group
Group type: COMPARATOR
Intervention: Controls (ulcer naïve)
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of sensation
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPI (ankle-brachial pressure index)
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot deformity
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ score
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: History of foot surgery
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar pressures and joint counts
Number of subjects: 273
Study 24310107 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected cutaneous vasculitis
Number of subjects: 273
Study 22473785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia
Number of subjects: 9
Study 22473785 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (control)
Number of subjects: 9
Study 19733660 — intervention group
Group type: EXPERIMENTAL
Intervention: gelatin capsules loaded with fast‐disintegrating starch pellets (group P)
Number of subjects: 18
Study 19733660 — intervention group
Group type: EXPERIMENTAL
Intervention: lyophilized lactose/skimmed milk (group L)
Number of subjects: 18
Study 19733660 — intervention group
Group type: COMPARATOR
Intervention: no intervention (group C)
Number of subjects: 18
Study 19733660 — intervention group
Group type: EXPERIMENTAL
Intervention: all groups (P, L, C)
Number of subjects: 18
Study 17513815 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (4 to 8 calls over 1 month)
Number of subjects: 305
Study 17513815 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 305
Study 12601075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (target INR, 1.5 to 2.0)
Number of subjects: 508
Study 12601075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 12601075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 508
Study 10959813 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon combined with ribavirin (1000-1200 mg/day) for 24 weeks
Number of subjects: 112
Study 10959813 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (5 million units, 3 times a week)
Number of subjects: 112
Study 8899116 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (10(-6)M)
Number of subjects: 8
Study 8899116 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (10(-5)M)
Number of subjects: 8
Study 8899116 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (10(-6)M) and Terbutaline (10(-5)M)
Number of subjects: 8
Study 1654194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) treatment with 370 mg of monoclonal antibody 494/32 (100 mg loading dose, 9 x 30 mg continuing within 10 days)
Number of subjects: 61
Study 1654194 — intervention group
Group type: COMPARATOR
Intervention: No additional anti-cancer treatment (Control)
Number of subjects: 61
Study 6352612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 275
Study 6352612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and tobramycin combination
Number of subjects: 275
Study 30506594 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation in Kangaroo position
Number of subjects: 66
Study 30506594 — intervention group
Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 66
Study 30506594 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation in Kangaroo position initiated before five days of life
Number of subjects: 66
Study 27649930 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 301
Study 26089136 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-Release Sarpogrelate 300 mg once daily
Number of subjects: 32
Study 26089136 — intervention group
Group type: COMPARATOR
Intervention: Immediate-Release Sarpogrelate 100 mg three times daily
Number of subjects: 32
Study 26089136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 32
Study 26089136 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-Release Sarpogrelate
Number of subjects: 32
Study 26089136 — intervention group
Group type: COMPARATOR
Intervention: Immediate-Release Sarpogrelate
Number of subjects: 32
Study 23387338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan-type rapid maxillary expansion (FRME)
Number of subjects: 42
Study 23387338 — intervention group
Group type: COMPARATOR
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 42
Study 21629370 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 78
Study 21629370 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture
Number of subjects: 78
Study 21629370 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 78
Study 21629370 — intervention group
Group type: COMPARATOR
Intervention: Actigraphy measures
Number of subjects: 78
Study 21629370 — intervention group
Group type: COMPARATOR
Intervention: Depressive symptoms
Number of subjects: 78
Study 21629370 — intervention group
Group type: COMPARATOR
Intervention: Daily functioning
Number of subjects: 78
Study 21629370 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic consumption
Number of subjects: 78
Study 19083075 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of vitamin D3 daily
Number of subjects: 131
Study 19083075 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of vitamin D3 daily
Number of subjects: 131
Study 19083075 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg of vitamin D3 daily
Number of subjects: 131
Study 19083075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of vitamin D3 daily
Number of subjects: 131
Study 19083075 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of vitamin D3 daily
Number of subjects: 131
Study 19083075 — intervention group
Group type: EXPERIMENTAL
Intervention: S-calcium (not specified dosage)
Number of subjects: 131
Study 16784967 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg before each meal (300 mg/d) for 3 months
Number of subjects: 20
Study 16784967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acarbose)
Number of subjects: 20
Study 16344404 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN/HYD therapy
Number of subjects: 0
Study 10596659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,200 mg amoxicillin‐clavulanic acid
Number of subjects: 54
Study 10596659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg cefuroxime
Number of subjects: 54
Study 10596659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8691923 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH treatment (subcutaneous dose ranged between 12.2 and 21.0 U/m2 per week for the first 2 years, then 20 U/m2 per week thereafter)
Number of subjects: 23
Study 8691923 — intervention group
Group type: COMPARATOR
Intervention: Observation group (7 short children who declined treatment)
Number of subjects: 23
Study 1679324 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Therapy (RET)
Number of subjects: 21
Study 1679324 — intervention group
Group type: EXPERIMENTAL
Intervention: exposure in vivo
Number of subjects: 21
Study 1679324 — intervention group
Group type: EXPERIMENTAL
Intervention: exposure in vivo (after RET)
Number of subjects: 21
Study 1679324 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 21
Study 7114076 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy
Number of subjects: 88
Study 7114076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 7114076 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with autoimmune features
Number of subjects: 88
Study 7114076 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without autoimmune features
Number of subjects: 88
Study 31157528 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive bonding of other group members in the middle of the group
Number of subjects: 168
Study 31157528 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual group member negative relationships in early and middle sessions
Number of subjects: 168
Study 31157528 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive working early in the group
Number of subjects: 168
Study 29044718 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐ and Family‐Focused Cognitive Behavioral Therapy (CFF‐CBT)
Number of subjects: 71
Study 29044718 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy treatment‐as‐usual (TAU)
Number of subjects: 71
Study 26883141 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-based CCRT (carboplatin AUC: 2, paclitaxel 35mg/m²) followed by TC-based consolidation chemotherapy (carboplatin AUC: 5, paclitaxel 175mg/m²)
Number of subjects: 31
Study 25402544 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) twice daily (bid)
Number of subjects: 100
Study 25402544 — intervention group
Group type: COMPARATOR
Intervention: Telaprevir (TVR) every 8-h (q8h)
Number of subjects: 100
Study 22538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 20
Study 22538078 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 20
Study 19732888 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 19732888 — intervention group
Group type: COMPARATOR
Intervention: Combined metformin and clomiphene citrate
Number of subjects: 0
Study 18507956 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced dressings
Number of subjects: 200
Study 18507956 — intervention group
Group type: COMPARATOR
Intervention: Traditional medications
Number of subjects: 200
Study 16005564 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 975
Study 16005564 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 975
Study 16005564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study 16005564 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg and 10 mg
Number of subjects: 975
Study 11840081 — intervention group
Group type: COMPARATOR
Intervention: Full dose Hib polysaccharide-tetanus toxoid conjugate vaccine
Number of subjects: 168
Study 11840081 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10 dilution of Hib polysaccharide-tetanus toxoid conjugate vaccine
Number of subjects: 168
Study 10354656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (1,200 mg)
Number of subjects: 16
Study 10354656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8577796 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (70 mg)
Number of subjects: 67
Study 8577796 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (250 mg)
Number of subjects: 67
Study 8577796 — intervention group
Group type: COMPARATOR
Intervention: Caffeine deprivation (overnight)
Number of subjects: 67
Study 8577796 — intervention group
Group type: COMPARATOR
Intervention: Caffeine deprivation (at least 7 days)
Number of subjects: 67
Study 1959958 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days
Number of subjects: 418
Study 1959958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 418
Study 1959958 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days (if started by 16-19 weeks of gestation)
Number of subjects: 418
Study 31675919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600,000 IU of 25(OH)D in a single oral administration)
Number of subjects: 700
Study 31675919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 29246284 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-DAG (2.5 g/day)
Number of subjects: 17
Study 29246284 — intervention group
Group type: COMPARATOR
Intervention: ALA-TAG (2.5 g/day)
Number of subjects: 17
Study 26672246 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter group (stellate ganglion catheter retention with ropivacaine block 1 time/day)
Number of subjects: 126
Study 26672246 — intervention group
Group type: EXPERIMENTAL
Intervention: Block group (stellate ganglion puncture and ropivacaine block 1 time/day)
Number of subjects: 126
Study 26672246 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine comprehensive treatment only)
Number of subjects: 126
Study 23301821 — intervention group
Group type: EXPERIMENTAL
Intervention: NBoNT (20 U)
Number of subjects: 314
Study 23301821 — intervention group
Group type: COMPARATOR
Intervention: OBoNT (20 U)
Number of subjects: 314
Study 23301821 — intervention group
Group type: EXPERIMENTAL
Intervention: NBoNT and OBoNT
Number of subjects: 314
Study 21471262 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion starting after induction of anesthesia with an initial bolus of 12 μg·kg(‐1) for 10 min, followed by 0.1 μg·kg(‐1)·min(‐1) for 24 h
Number of subjects: 40
Study 21471262 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump started 16‐18 h before surgery
Number of subjects: 40
Study 21471262 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion
Number of subjects: 40
Study 19398080 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) training for 8 weeks, 1 hour, 5 days a week
Number of subjects: 10
Study 15121557 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 600 microg misoprostol
Number of subjects: 169
Study 15121557 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of 600 microg misoprostol
Number of subjects: 169
Study 11477729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized INS 365 (20, 40, 80, and 100 mg)
Number of subjects: 84
Study 11477729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized INS 365 (80 mg and 100 mg)
Number of subjects: 84
Study 11477729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 84
Study 11477729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized INS 365
Number of subjects: 84
Study 9928921 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 43
Study 8035394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated naproxen (NAP‐EC)
Number of subjects: 355
Study 8035394 — intervention group
Group type: COMPARATOR
Intervention: Standard immediate release naproxen (NAP‐STD)
Number of subjects: 355
Study 3059882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized atropine methylnitrate (AMN)
Number of subjects: 22
Study 3059882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31220920 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate workbook (ACT self-help bibliotherapy)
Number of subjects: 503
Study 31220920 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (control)
Number of subjects: 503
Study 30969313 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26797777 — intervention group
Group type: EXPERIMENTAL
Intervention: Radica plasma disinfection system
Number of subjects: 27
Study 26797777 — intervention group
Group type: COMPARATOR
Intervention: Standard cleaning
Number of subjects: 27
Study 25312436 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide (4/1.25 mg)
Number of subjects: 11140
Study 23437857 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent-only intervention program (12 group sessions over 4 months)
Number of subjects: 1
Study 21041512 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized orthoses using the D3D system
Number of subjects: 400
Study 21041512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthoses)
Number of subjects: 400
Study 18841741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic toothbrush
Number of subjects: 20
Study 18841741 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 20
Study 16320073 — intervention group
Group type: EXPERIMENTAL
Intervention: CK19 mRNA levels during operation
Number of subjects: 33
Study 16320073 — intervention group
Group type: EXPERIMENTAL
Intervention: CK19 mRNA levels between adenocarcinoma and squamous carcinoma
Number of subjects: 33
Study 16320073 — intervention group
Group type: EXPERIMENTAL
Intervention: CK19 mRNA levels between PV-first group and PA-first group
Number of subjects: 33
Study 16320073 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA mRNA levels during operation
Number of subjects: 33
Study 16320073 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA mRNA levels between PV-first group and PA-first group
Number of subjects: 33
Study 16320073 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between preoperative T-stage and perioperative CEA mRNA
Number of subjects: 33
Study 16320073 — intervention group
Group type: COMPARATOR
Intervention: Detection of circulating epithelial cells in benign lung disease patients
Number of subjects: 33
Study 14516415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg, p.o.)
Number of subjects: 50
Study 14516415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10793605 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms
Number of subjects: 64
Study 10793605 — intervention group
Group type: COMPARATOR
Intervention: Saline 1 ml
Number of subjects: 64
Study 8859174 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional infusion chemotherapy with FUDR
Number of subjects: 0
Study 8859174 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 1534472 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (5, 10, 15, or 20 micrograms/kg IV)
Number of subjects: 48
Study 1534472 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (30 micrograms/kg IV)
Number of subjects: 48
Study 1534472 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (5, 10, 20, or 40 micrograms/kg)
Number of subjects: 48
Study 1534472 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (to obtain 70% train-of-four recovery after 10 min)
Number of subjects: 48
Study 2983461 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir 200 mg X 4 daily for 28 days
Number of subjects: 35
Study 2983461 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 2983461 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir (after interruption of placebo)
Number of subjects: 35
Study 2983461 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir and placebo
Number of subjects: 35
Study 31664468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 100-150 mg/kg/min
Number of subjects: 90
Study 31664468 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane ≤ 1 MAC
Number of subjects: 90
Study 29521134 — intervention group
Group type: EXPERIMENTAL
Intervention: Tylerdipine hydrochloride (5, 15, 20, 25, and 30 mg)
Number of subjects: 127
Study 30514716 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 0
Study 30514716 — intervention group
Group type: COMPARATOR
Intervention: Meniscectomy
Number of subjects: 0
Study 26574928 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with fixed appliance for 6 months
Number of subjects: 120
Study 26574928 — intervention group
Group type: COMPARATOR
Intervention: Control group awaiting treatment
Number of subjects: 120